Please join this free webinar to hear from industry experts at PRA Health Sciences and The Leukemia & Lymphoma Society (LLS) regarding the collaborative efforts critical for the success of the Research to Accelerate Cures and Equity (RACE) for Children Act.
The open discussion format will be prefaced by a short iteration on what the RACE for Children Act is, followed by key industry leaders highlighting what is being done now and what needs to continue and be improved upon to ensure that the RACE Act has the intended impact: safe and effective treatments for children diagnosed with cancer.
Learn about the ground breaking LLS PedAL Trial and the monumental collaboration already underway among non-profits, industry pharma partners, pediatric consortia, genomics providers and Clinical Research Organizations (CROs).
Together we will find the cure.
Gwen Nichols, MD, Chief Medical Officer, Leukemia & Lymphoma Society, Co-Chair PedAL Initiative
As LLS’s chief medical officer, Dr Gwen Nichols plays a critical role in advancing cures through a unique combination of clinical, academic and pharmaceutical experience. She oversees LLS’s scientific research portfolio, patient services and policy and advocacy initiatives. A physician and scientific researcher, she has dedicated her career to advancing cures for cancers.
Most recently, Dr Nichols was oncology site head of the Roche Translational Clinical Research Center, where she worked to develop new cancer therapies, translating them from the laboratory to clinical trials. Prior to joining Roche in 2007, Dr Nichols was at Columbia University for more than ten years, where she served as the director of the Hematologic Malignancies Program.
While at Columbia University, Dr Nichols maintained an active clinical practice and received the prestigious honors of “Physician of the Year” from Columbia University and the “Humanism in Medicine Award” from the American Association of Medical Colleges.
Dr Nichols trained in internal medicine at the University of Chicago and completed post-doctoral research and a hematology-oncology fellowship at Memorial Sloan-Kettering Cancer Center where she was an attending physician. She received her medical degree with honors from the State University of New York at Buffalo.Message Presenter
E. Anders (Andy) Kolb, MD, Director, Blood & Bone Marrow Transplantation, Nemours Children’s Health System, Nemours Center for Cancer and Blood Disorders, Co-Chair, PedAL Initiative
Dr Kolb spends about half his time treating kids who have cancer and their families and making daily life easier for them. The other half, he spends heavily involved with advanced research programs to find new cancer drugs that are more effective, with fewer side effects. These programs help kids with cancer today and in the future. The common theme to his laboratory and clinical work has been the efficient and effective translation of novel therapies into children.
As a founding member of the National Cancer Institute (NCI)-funded Pediatric Preclinical Testing Program, Dr Kolb successfully completed preclinical evaluations of numerous anti-cancer strategies in human tissues and aided in the translation of these agents into clinical trials. His expertise is in genomics, proteomics and cell signaling research to support the critical rationale needed for effective translational medicine.
Within the Children’s Oncology Group (COG), Dr Kolb serves as the Chair of the Myeloid Disease Committee and Member of the Scientific Council. He is Co-Chair of The Leukemia & Lymphoma Society Pediatric Acute Leukemia Initiative (LLS PedAL). Through this work, his focus is on collaborative science, resource stewardship, clinical research development, clinical trial design and implementation and in the necessities new agent development.
Dr Kolb attained an undergraduate degree from the University of Pennsylvania and a medical degree from Jefferson Medical College. He completed a residency in pediatrics at St. Christopher’s Hospital for Children followed by a fellowship in Pediatric Hematology and Oncology at Memorial Sloan-Kettering Cancer Center.Message Presenter
Joanna Perkins, MD, MS, Medical Director, Hematology/Oncology, PRA Health Sciences
Dr Joanna Perkins joined PRA Health Sciences in 2018 and serves as a medical director of hematology and oncology. She supports all medical aspects of study development for global clinical trials and provides medical monitoring throughout study conduct. She leads disease-specific therapeutic training for project team members. She also serves as a manager within the hematology-oncology division at PRA.
Dr Perkins is a member of the Pediatric Collaborative Team of PRA’s Center for Pediatric Clinical Development. This multidisciplinary team of pediatric experts supports all PRA-conducted projects involving pediatric product development by providing strategic consulting services as a single cross-functional global resource.
Prior to joining PRA, Dr Perkins was in clinical practice for 15 years with a focus on pediatric, adolescent and young adult leukemias and lymphomas, as well as a clinical research focus on the long-term complications of childhood cancer treatment. She served as Site Principal Investigator for the North American multi-institutional Childhood Cancer Survivor Study. She also served as the physician advisor to the marketing and communications, outreach, patient and family satisfaction and philanthropy teams of a large metropolitan pediatric health care system.
Dr Perkins is board certified in pediatrics and in pediatric hematology and oncology. She received her undergraduate and medical degrees at the University of Minnesota, where she also completed residency and fellowship and a received a Master of Science degree in Clinical Research.Message Presenter
Missy Hansen, MSN, APRN, CNP-Pediatrics, Center for Pediatric Clinical Development, PRA Health Sciences
Ms Hansen joined PRA Health Sciences in 2019 and serves as a Pediatric Strategy Liaison in PRA’s Center for Pediatric Clinical Development, with a specific focus on pediatric oncology and the RACE for Children Act. Ms Hansen has over 26 years of experience as a pediatric nurse practitioner with the most recent 15 years in pediatric hematology/oncology. Her previous institution is one of the largest in her area and provides care for infants through young adults diagnosed with hematological and/or oncological conditions. Ms Hansen gained a broad range of knowledge for this specialized group of patients by working in inpatient, outpatient and urgent care type settings. Ms Hansen has in depth experience working with Children’s Oncology Group, which is the largest consortia with the greatest number of pediatric studies open across the world, and she also has experience with other consortiums offering pediatric to young adult trial options to patients. Ninety percent of eligible patients to be treated on a trial were enrolled on study at Hansen’s most recent clinical care institution
Learn about the ground breaking Leukemia & Lymphoma Society Pediatric Acute Leukemia Trial (LLS PedAL) and the monumental collaboration already underway among non-profits, industry pharma partners, pediatric consortia, genomics providers and Clinical Research Organizations (CROs).Message Presenter
Who Should Attend?
- Regulatory Affairs
- Scientific Affairs
- Risk Management
- Project Management
- Clinical Research
- Medical Affairs
- Clinical Affairs
- Research and Development
- Clinical Operations
- Health care providers
- Advocacy groups and their members
- Anyone who has an interest in the future of pediatric oncology
What You Will Learn
- Why the Research to Accelerate Cures and Equity (RACE) for Children Act (being implemented August 18, 2020) is necessary
- The impact of the RACE Act on industry, especially the need for collaboration
- The types of collaboration that are critical for success
- Key challenges in implementing a master (umbrella) trial for pediatric oncology, based on current experience
- Identifying collaborative partners for a pediatric oncology master trial, and how to work together
PRA Health Sciences
PRA Health Sciences is a full-service, drug development organization, providing a broad range of product development and data solution services across all phases and a wide array of therapeutic areas to biopharmaceutical companies. PRA operates in 85+ countries, with over 15,800 employees worldwide. PRA’s Real World Solutions team works exclusively in the real world research arena. Our real world evidence studies connect the companies that design and market revolutionary therapies with the patients who benefit from them and our teams innovate ways to capture, analyze, and qualify product performance — and patient experience — in the real world.